This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Oncolytic viruses for boosting efficacy of dendritic cell (DC) cancer immunotherapy	<p>Virus-induced tumor inflammation could help boost the efficacy of DC-based cancer immunotherapies. In tumor-bearing mice, DC-based cancer immunotherapy three days after intratumoral injection of an inflammatory oncolytic virus lowered tumor growth compared with either treatment alone ($p < 0.05$). In the same mice, depletion of T_{reg} cells blocked the antitumor effects of the combination therapy. Next steps include evaluating the use of an oncolytic virus in the adjuvant setting with other types of immunotherapy.</p> <p>SciBX 4(25); doi:10.1038/scibx.2011.725 Published online June 23, 2011</p>	Unpatented; licensing status not applicable	<p>Woller, N. <i>et al. J. Clin. Invest.</i>; published online June 6, 2011; doi:10.1172/JCI45585</p> <p>Contact: Stefan Kubicka, Hannover Medical School, Hannover, Germany e-mail: kubicka.stefan@mh-hannover.de</p> <p>Contact: Florian Kühnel, same affiliation as above e-mail: kuehnel.florian@mh-hannover.de</p>